AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Socie...
April 13 2020 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced that results from the CONVERGE IDE
trial have been accepted for presentation in the late-breaking
abstract sessions at the Heart Rhythm Society (HRS) Scientific
Sessions. The abstract will be presented as a webinar on Heart
Rhythm 365, the society’s digital information platform. Specific
details on the exact timing of the presentation will follow in a
separate announcement.
“I want to thank the HRS for accepting the abstract for
presentation during the virtual programming as part of the annual
meeting,” said Dr. David B. DeLurgio, Director of Electrophysiology
at the Emory Heart and Vascular Center at Emory St. Joseph’s
Hospital, and National Principal Investigator for the CONVERGE
trial. “I’m grateful for the opportunity to present on this very
important trial.”
About CONVERGE IDE Trial
The CONVERGE IDE trial is a landmark prospective, randomized
trial comparing the Convergent approach to endocardial catheter
ablation for patients with persistent or long-standing persistent
Afib. The Convergent approach is a multi-disciplinary therapy in
which a closed chest epicardial ablation is performed by a surgeon,
and then complemented by an endocardial catheter ablation performed
by an electrophysiologist. Patients were enrolled at 25 sites
across the United States, along with two sites in the United
Kingdom.
The CONVERGE study’s primary efficacy endpoint is for enrolled
patients to be free from Afib, atrial tachycardia, and atrial
flutter, absent class I and III AADs except for a previously failed
or intolerant class I or III anti-arrhythmic drugs, with no
increase in dosage following the three month blanking period
through the 12 months post procedure follow-up visit. The company
has submitted final documentation to the Food and Drug
Administration and is seeking a pre-market approval (PMA).
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit AtriCure.com or
follow us on Twitter @AtriCure.
Forward-Looking
Statements
This press release contains “forward-looking statements”– that
is, statements related to future events that by their nature
address matters that are uncertain. For details on the
uncertainties that may cause our actual results to be materially
different than those expressed in our forward-looking statements,
visit http://www.atricure.com/fls as well as our Annual Reports on
Form 10-K and Quarterly Reports on Form 10-Q which contain risk
factors. We do not undertake to update our forward-looking
statements. This document also includes forward-looking projected
financial information that is based on current estimates and
forecasts. Actual results could differ materially.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200413005090/en/
Andy Wade AtriCure, Inc. Chief Financial Officer (513) 755-4564
awade@atricure.com Lynn Pieper Lewis Gilmartin Group Investor
Relations (415) 937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024